DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo
about
Recent advances in vaccine development for herpes simplex virus types I and IILong-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccineHerpes simplex virus type 2 vaccines: new ground for optimism?Herpes simplex virus and the chemokines that mediate the inflammation.Fighting infection using immunomodulatory agents.Suppression of proinflammatory cytokine expression by herpes simplex virus type 1.Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaquesIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Modulating the innate immune response by combinatorial engineering of endotoxinHerpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections.Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.Increased incidence of skin infections in atopy: evidence for an antigen-specific homing defect?Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infectionNext generation DNA vaccines for HIV-1.Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function.Activation and evasion of innate antiviral immunity by herpes simplex virusSystemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilizationEnhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.Molecular adjuvants for mucosal immunity.Developing DNA vaccines that call to dendritic cells.The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous systemEffects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.Optimization and delivery of plasmid DNA for vaccination.Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvantProphylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusChemokines and Chemokine Receptors Critical to Host Resistance following Genital Herpes Simplex Virus Type 2 (HSV-2) InfectionVaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infectionAn intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virusSynthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.DNA vaccines for targeting bacterial infections.The ongoing pursuit of a prophylactic HSV vaccine.Chemokine-based immunotherapy: delivery systems and combination therapies.Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection.Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.
P2860
Q26859623-728B98E5-7487-4E25-A7D4-83486B0678A0Q28743435-42A37161-0408-48D8-AFE7-19B20C06750EQ33711912-DD78B6F5-B114-4924-B841-046EE25F2ABDQ33825406-56204EDF-6FF6-4204-994B-734245C80997Q34103603-658C13CB-E4F7-475F-8B9E-789215C9B564Q34152457-BB91CD32-0BF4-4075-B548-CAFD4C4CA550Q34290878-62146EEE-1029-428A-B70A-C9153AF067CFQ34309830-B64FCF4C-6C86-44D5-8EBE-B432085B77F1Q34321369-47E8C024-06B7-4327-BCFB-045C58ECA74EQ34332533-388B82B2-28A9-4A16-B74B-D4B056F7710FQ34452049-861B249D-A98C-41CE-AFD4-6CA2189567E7Q34529742-95A9D448-42C7-4399-9262-AD3AEE015CFAQ34585480-7728AB57-9492-4CE6-A901-197F57C0C0B1Q34694776-ADEB9002-1D1D-4EEF-98E5-1A4AE41079FBQ35072785-5E7988F3-4B8B-4031-98A7-B4C6FCB6B232Q35101552-21C820A5-0C15-491B-9CB1-FF9A98C15E88Q35209368-9DDF62D5-BB32-4314-BCA8-D8597BAD9313Q35259878-0A00923B-6B58-4F2C-9B77-1DD8088DBDFEQ35413374-017D2376-AE81-43CC-B03A-6D3DEAB455B4Q35469531-5244E9CC-51AC-479D-8C74-1A73B9D9D19CQ35785221-4278D128-AC7C-4EF1-A30B-28896DCDE2A7Q35826378-2411D9B0-DBA5-4F4C-9C11-86A8282CC18CQ35826381-41E8AA39-E1FC-4584-910D-4BC863FBE9ECQ35936512-6D6F9FC7-AA88-4682-88FC-64C02CFA49BCQ35951849-3126219F-01EB-4707-B751-3B09C1BFF721Q36343355-556CD017-1944-47DF-8FB3-7DEB50B2FEB2Q36627931-B736027F-E57F-4260-B0EB-E769EBCF14ACQ36690285-F5B2D688-E965-43D4-A94E-2E045D5FECE5Q36694830-FA9E40DB-8C52-4EF1-8CE6-844F7E0CF8EEQ36879345-0689F242-C4D9-470C-A883-3E9105DF25E2Q36981179-CC56BFD7-BB7F-47EB-90EC-3DC2B6A462E1Q37127506-9D81552F-360F-473E-AA60-1618BF745D74Q37180994-B0B29C44-A349-4324-908E-38FC58EB2AEFQ37276912-166D01A6-626E-45D8-A978-19DF288D1CF4Q37771943-CE71AFC0-758B-431E-94F0-0A295EE5294AQ37991272-8C83EDCF-6088-4927-B921-83C392FC6A9BQ38040509-106B1F9A-CC7D-4317-8165-156E7C0BB5ECQ38730774-048BA23E-1817-43ED-93D4-01C98CDA7CEAQ39221171-4261B224-1505-4A5F-8B57-C595E78D6A39Q40247465-1E1C12A0-7C95-4A24-899A-9CD578EA92FE
P2860
DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@ast
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@en
type
label
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@ast
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@en
prefLabel
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@ast
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@en
P2093
P2860
P1433
P1476
DNA vaccines encoding interleu ...... s simplex virus type 2 in vivo
@en
P2093
P2860
P304
11173-11180
P356
10.1128/JVI.74.23.11173-11180.2000
P577
2000-12-01T00:00:00Z